CliffBio
biologic

Sylvant

siltuximab

Loss of exclusivityApril 2026projected — 12-year biologic exclusivity estimate
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameSylvant
Active ingredientsiltuximab
Strength100MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2014
Marketing statusRx

More from Recordati Rare Diseases Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sylvant patent cliff — loss of exclusivity April 2026 | CliffBio